Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

12.8K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

8.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.9K
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

9.2K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.2K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

8.0K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiogenomic approach combining CT-based radiomics and liquid biopsy improves prognostic stratification in patients with advanced NSCLC.

The journal of liquid biopsy·2026
Same author

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): 'Where the streets have no name'.

Critical reviews in oncology/hematology·2026
Same author

Long-Term Oncological Outcomes of Minimally Invasive Surgery in Non-Small Cell Lung Cancer: An Updated Review.

Cancers·2026
Same author

Actionable driver gene alterations in early-stage non-small cell lung cancer: a review.

Therapeutic advances in medical oncology·2026
Same author

Lorlatinib atypical safety profile in ALK-positive aNSCLC: tips for management from an Italian expert panel.

Future oncology (London, England)·2026

Related Experiment Video

Updated: Sep 13, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List.

Ilaria Attili1, Federico Pio Fabrizio2, Filippo de Marinis1

  • 1Division of Thoracic Oncology, European Institute of Oncology, IEO, IRCCS, 20141 Milan, Italy.

Cancers
|July 29, 2025
PubMed
Summary

Co-occurring mutations in non-small cell lung cancer (NSCLC) complicate targeted therapies. Understanding these complex genomic alterations is crucial for developing effective, personalized treatment strategies and improving patient outcomes.

Keywords:
co-occurring genomic alterationsmolecular profilingnon-small cell lung cancertargeted therapiestyrosine kinase inhibitors

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.7K

Related Experiment Videos

Last Updated: Sep 13, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.5K
Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
09:49

Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing

Published on: July 5, 2019

9.7K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer worldwide, with targeted therapies like tyrosine kinase inhibitors (TKIs) improving outcomes for oncogene-addicted NSCLC.
  • Tumor complexity involves co-occurring genomic alterations (co-mutations) in genes such as TP53, STK11, KEAP1, PIK3CA, and RB1, which impact disease progression and treatment resistance.

Purpose of the Study:

  • To synthesize current insights into co-mutations in NSCLC, focusing on their clinical implications and therapeutic challenges.
  • To provide a novel perspective integrating molecular insights with therapeutic resistance mechanisms in NSCLC.
  • To address knowledge gaps through a clinically oriented analysis of co-mutations.

Main Methods:

  • Review of current literature on NSCLC co-mutations.
  • Analysis of next-generation sequencing (NGS) data and molecular profiling findings.
  • Integration of molecular insights with clinical outcomes and therapeutic resistance.

Main Results:

  • Co-mutations significantly influence NSCLC biology, disease progression, and resistance to targeted therapies.
  • Advances in NGS enable identification of co-alterations, supporting personalized medicine.
  • Challenges persist in interpreting the functional interplay of co-mutations and translating findings into clinical practice.

Conclusions:

  • Co-mutations are critical determinants of therapeutic response and resistance in NSCLC.
  • Integrative, biomarker-driven approaches are essential for improving NSCLC treatment outcomes.
  • Further research is needed to elucidate the functional impact of co-mutations and optimize therapeutic strategies.